Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FA-HES-EPI
- Development stage
- Preclinical
- Lead developer
- Shenyang Pharmaceutical University
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravesical
01
Overview
FA-HES-EPI is a pH-responsive, tumor-targeted polymer-drug conjugate designed for the treatment of bladder cancer. It consists of the chemotherapeutic agent epirubicin (EPI) covalently linked to a hydroxyethyl starch (HES) backbone via an acid-sensitive hydrazone bond, with folic acid (FA) moieties attached to provide active targeting to folate receptor-overexpressing tumor cells. The hydroxyethyl starch serves as a biocompatible nanocarrier that improves the solubility and pharmacokinetic profile of epirubicin. Upon internalization into the acidic tumor microenvironment or endosomes, the hydrazone bond cleaves, releasing the active epirubicin payload. This system is often formulated into micelles and has been investigated for the co-delivery of immune modulators like imiquimod to achieve synergistic chemoimmunotherapy.
- Other names
- folate-conjugated hydroxyethyl starch-epirubicinFA-HES-EPI micellesfolate-modified hydroxyethyl starch-epirubicin prodrug
02
Targets
FOLR1 (FRα)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on FA-HES-EPI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FA-HES-EPI.